Edition:
United States

Genmab A/S (GEN.CO)

GEN.CO on Copenhagen Stock Exchange

1,052.50DKK
17 Aug 2018
Change (% chg)

kr.0.50 (+0.05%)
Prev Close
kr.1,052.00
Open
kr.1,053.00
Day's High
kr.1,075.50
Day's Low
kr.1,051.00
Volume
95,544
Avg. Vol
222,391
52-wk High
kr.1,474.00
52-wk Low
kr.880.80

Latest Key Developments (Source: Significant Developments)

Genmab To Pay Seattle Genetics, Inc. Milestone Payment Of USD 7 Million
Friday, 29 Jun 2018 10:19am EDT 

June 29 (Reuters) - GENMAB A/S ::TO PAY SEATTLE GENETICS, INC. A MILESTONE PAYMENT OF USD 7 MILLION UNDER ANTIBODY-DRUG CONJUGATE (ADC) PROGRAM TARGETING AXL.MILESTONE TRIGGERED BY CLINICAL PROGRESS IN PHASE I/II STUDY OF HUMAX(®)-AXL-ADC IN SEVEN DIFFERENT SOLID TUMORS.DOES NOT IMPACT GENMAB'S 2018 FINANCIAL GUIDANCE..  Full Article

Genmab Topline Results From Phase III Study Did Not Meet Primary Endpoint
Thursday, 24 May 2018 10:20am EDT 

May 24 (Reuters) - Genmab A/S ::REG-GENMAB ANNOUNCES TOPLINE RESULTS IN PHASE III STUDY OF ARZERRA® IN INDOLENT NON-HODGKIN’S LYMPHOMA.TOPLINE RESULTS FROM PHASE III STUDY IN INHL DID NOT MEET PRIMARY ENDPOINT OF IMPROVED PROGRESSION-FREE SURVIVAL.RESULTS FROM THIS PHASE III STUDY DO NOT IMPACT ANY OTHER ONGOING STUDIES WITH OFATUMUMAB..RESULTS FROM PHASE III STUDY OF ARZERRA(®) (OFATUMUMAB) PLUS BENDAMUSTINE DID NOT MEET PRIMARY ENDPOINT.RESULTS FROM PHASE III STUDY DO NOT IMPACT ANY OTHER ONGOING STUDIES WITH OFATUMUMAB..SAFETY PROFILE OBSERVED IN THIS STUDY WAS CONSISTENT WITH THAT OBSERVED IN OTHER TRIALS OF OFATUMUMAB AND NO NEW SAFETY SIGNALS WERE OBSERVED..  Full Article

Genmab Gets USD 50 Mln From Novartis For Lost Potential Milestones And Royalties​
Monday, 22 Jan 2018 02:06am EST 

Jan 22 (Reuters) - GENMAB ::ANNOUNCES NOVARTIS’ INTENTION TO TRANSITION ARZERRA® (OFATUMUMAB) FROM COMMERCIAL AVAILABILITY TO LIMITED AVAILABILITY VIA COMPASSIONATE USE PROGRAMS FOR THE TREATMENT OF CLL IN NON-US MARKETS.‍RECEIVES USD 50 MILLION FROM NOVARTIS AS PAYMENT FOR LOST POTENTIAL MILESTONES AND ROYALTIES​.‍AMOUNT WILL BE INCLUDED IN GENMAB'S 2018 GUIDANCE​.‍ROYALTIES WILL CONTINUE TO BE EARNED ON NET SALES OF ARZERRA​.  Full Article

Gemnab Says Artisan Partners Increased Indirect Ownership In Co To 5.04 Pct Of Share Capital and Voting Rights
Tuesday, 9 Jan 2018 02:58pm EST 

Jan 9 (Reuters) - Genmab A/S ::GENMAB - ‍ARTISAN PARTNERS INCREASED THEIR INDIRECT OWNERSHIP IN CO TO 3,081,731 SHARES, AMOUNTING TO 5.04% OF SHARE CAPITAL, VOTING RIGHTS IN CO.MAJOR SHAREHOLDER ANNOUNCEMENT.  Full Article

Biotech Genmab sees 2018 expense growth of 40-50 pct
Tuesday, 12 Dec 2017 01:27am EST 

Dec 12 (Reuters) - FOLLOWING ARE STATEMENTS FROM GENMAB'S R'N'D UPDATE IN ATLANTA, GEORGIA: :DENMARK'S GENMAB SEES 2018 EXPENSE GROWTH OF 40-50 PERCENT DRIVEN BY PIPELINE INVESTMENTS.SAYS ROYALTY FUNDS 100 PCT OF EXPENSE INVESTMENT.GENMAB TO CONDUCT NEW AND LARGER TISOTUMAB VEDOTIN TRIALS IN 2018.SAYS 6 PRE-CLINICAL PRODUCTS RAPIDLY ADVANCING.SAYS 2018 WILL BE 6TH YEAR OF PROFITABILITY.  Full Article

Genmab Achieves $20 Million Milestone In Daratumumab Collaboration With Janssen
Wednesday, 29 Nov 2017 03:42pm EST 

Nov 29 (Reuters) - Genmab A/S ::GENMAB ACHIEVES USD 20 MILLION MILESTONE IN DARATUMUMAB COLLABORATION WITH JANSSEN AND UPDATES FINANCIAL GUIDANCE.GENMAB - EXPECT 2017 REVENUE TO BE IN RANGE OF DKK 2,240 - 2,440 MILLION.GENMAB - PAYMENT RELATES TO PHASE III ANDROMEDA STUDY OF DARATUMUMAB IN COMBINATION WITH CYCLOPHOSPHAMIDE, BORTEZOMIB & DEXAMETHASONE IN AMYLOIDOSIS.  Full Article

Genmab: $50 mln milestone payment in collaboration on Darzalex
Thursday, 16 Nov 2017 09:31pm EST 

Nov 17(Reuters) - GENMAB A/S : :SAID ON FRIDAY WILL RECEIVE MILESTONE PAYMENT OF USD 50 MILLION IN DARZALEX COLLABORATION WITH JANSSEN BIOTECH, INC..SAID MILESTONE TRIGGERED BY SALES OF DARZALEX REACHING USD 1 BILLION IN A CALENDAR YEAR.THE MILESTONE WAS INCLUDED IN GENMAB’S 2017 FINANCIAL GUIDANCE PUBLISHED ON NOVEMBER 14, 2017.  Full Article

‍Genmab says expect 2017 revenue to be in range of DKK 2,110 – 2,310 mln
Tuesday, 14 Nov 2017 02:50pm EST 

Nov 14 (Reuters) - Genmab ::‍GENMAB ACHIEVES USD 25 MILLION MILESTONE FOR FIRST COMMERCIAL SALE OF DARZALEX® (DARATUMUMAB) IN JAPAN AND UPDATES FINANCIAL GUIDANCE​.GENMAB SAYS ‍EXPECT 2017 REVENUE TO BE IN RANGE OF DKK 2.110 - 2.310 MILLION​.GENMAB-EXPECT DARZALEX ROYALTIES TO REMAIN IN RANGE OF DKK 930 - 1,100 MILLION WHICH ARE BASED ON ESTIMATED USD 1,100 - 1,300 MILLION OF DARZALEX SALES IN 2017​.‍NOW EXPECT OPERATING INCOME FOR 2017 TO BE APPROXIMATELY DKK 1,060 - 1,260 MILLION, COMPARED TO DKK 900 - 1,100 MILLION IN PREVIOUS GUIDANCE​.  Full Article

Genmab Q3 net loss DKK 5.7 mln, misses estimates
Wednesday, 8 Nov 2017 11:01am EST 

Nov 8 (Reuters) - GENMAB A/S ::GENMAB ANNOUNCES FINANCIAL RESULTS FOR THE FIRST NINE MONTHS OF 2017 <<>>.‍REVENUE WAS DKK 1,348 MILLION IN FIRST NINE MONTHS OF 2017 COMPARED TO DKK 889 MILLION IN FIRST NINE MONTHS OF 2016​.‍OPERATING INCOME WAS DKK 641 MILLION IN FIRST NINE MONTHS OF 2017 COMPARED TO DKK 345 MILLION IN FIRST NINE MONTHS OF 2016​.‍IS MAINTAINING ITS 2017 FINANCIAL GUIDANCE PUBLISHED ON FEBRUARY 22, 2017 AND REITERATED ON SEPTEMBER 27, 2017​.Q3 REVENUE DKK ‍​ 323.4 MILLION (REUTERS POLL DKK 333 MILLION).Q3 OPERATING RESULT DKK ‍​ 58.3 MILLION (REUTERS POLL DKK 59 MILLION).Q3 NET LOSS DKK ‍​5.7 MILLION (REUTERS POLL PROFIT DKK 67.3 MILLION).  Full Article

Genmab: ‍worldwide net sales of darzalex $317 mln in Q3
Tuesday, 17 Oct 2017 06:52am EDT 

Oct 17 (Reuters) - GENMAB A/S :GENMAB ANNOUNCES NET SALES OF DARZALEX® (DARATUMUMAB) FOR THIRD QUARTER OF 2017.‍WORLDWIDE NET SALES OF DARZALEX (DARATUMUMAB) AS REPORTED BY JOHNSON & JOHNSON WERE USD 317 MILLION IN Q3 OF 2017​.‍GENMAB WILL RECEIVE ROYALTIES ON WORLDWIDE NET SALES FROM JANSSEN BIOTECH, INC.​.  Full Article

Danish biotech Genmab hit by ending of trial using key cancer drug

COPENHAGEN Shares in Danish biotech Genmab fell by as much as 25 percent on Monday after its partner Johnson & Johnson decided to ditch a study using its blockbuster cancer drug.